Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000304230 | SCV000338021 | likely pathogenic | not provided | 2018-03-14 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000811495 | SCV000951763 | uncertain significance | Qualitative or quantitative defects of dysferlin | 2022-08-15 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with lysine, which is basic and polar, at codon 2019 of the DYSF protein (p.Arg2019Lys). This variant also falls at the last nucleotide of exon 53, which is part of the consensus splice site for this exon. This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with clinical features of Limb-Girdle Muscular Dystrophy and/or clinical suspicion of limb-girdle muscular dystrophy (PMID: 30564623; Invitae). ClinVar contains an entry for this variant (Variation ID: 285133). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The lysine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |